Home
/
IOVANCE BIOTHERAPEUTICS, INC.
/
Financials
/
Quarterly
IOVANCE BIOTHERAPEUTICS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that IOVANCE BIOTHERAPEUTICS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2019
Mar 31, 2019
$0
May 7, 2019
Q3
2018
Sep 30, 2018
$0
Nov 6, 2018
Q2
2018
Jun 30, 2018
$0
Aug 7, 2018
Q1
2019
Mar 31, 2018
$0
May 7, 2019
Q3
2018
Sep 30, 2017
$0
Nov 6, 2018
Q2
2018
Jun 30, 2017
$0
Aug 7, 2018
Q1
2018
Mar 31, 2017
$0
May 10, 2018
Q3
2017
Sep 30, 2016
$0
Nov 2, 2017
Q2
2017
Jun 30, 2016
$0
Aug 3, 2017
Q1
2017
Mar 31, 2016
$0
May 3, 2017
Q3
2016
Sep 30, 2015
$0
Nov 4, 2016
Q2
2016
Jun 30, 2015
$0
Aug 9, 2016
Q1
2016
Mar 31, 2015
$0
May 9, 2016
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$67.46M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$59.95M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$49.32M
May 8, 2025
Q3
2025
Sep 30, 2024
$58.56M
Nov 6, 2025
Q2
2025
Sep 30, 2024
$31.11M
Aug 7, 2025
Q2
2025
Jun 30, 2024
$31.11M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$715.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$469.0K
Nov 7, 2024
Q2
2024
Jun 30, 2023
$238.0K
Aug 8, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($91.25M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($111.66M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($116.16M)
May 8, 2025
Q3
2025
Sep 30, 2024
($83.54M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($97.10M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($112.98M)
May 8, 2025
Q3
2024
Sep 30, 2023
($113.76M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($106.53M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($107.37M)
May 9, 2024
Q3
2023
Sep 30, 2022
($99.62M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($99.35M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($91.61M)
May 10, 2023
Q3
2022
Sep 30, 2021
($86.12M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($81.35M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($75.45M)
May 5, 2022
Q3
2021
Sep 30, 2020
($58.57M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($63.02M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($69.60M)
May 6, 2021
Q3
2020
Sep 30, 2019
($49.49M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($47.55M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($94.90M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($113.77M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($121.22M)
May 8, 2025
Q3
2025
Sep 30, 2024
($89.07M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($101.91M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($117.72M)
May 8, 2025
Q3
2024
Sep 30, 2023
($118.36M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($110.09M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($110.86M)
May 9, 2024
Q3
2023
Sep 30, 2022
($100.40M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($99.73M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($91.71M)
May 10, 2023
Q3
2022
Sep 30, 2021
($86.24M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($81.43M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($75.57M)
May 5, 2022
Q3
2021
Sep 30, 2020
($58.97M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($63.63M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($70.81M)
May 6, 2021
Q3
2020
Sep 30, 2019
($51.61M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($50.17M)
Aug 6, 2020